Market Overview

IBM Expands Its Watson Ecosystem In India


International Business Machines Corp. (NYSE: IBM) announced on Tuesday that two Indian-based firms, InspireOne Technologies and TEXTIENT will join the IBM Watson Ecosystem.

The companies will develop cognitive computing solutions in the region.

InspireOne Technologies will use Watson's cognitive APIs in its professional development app to empower employees to develop leadership skills. TEXTIENT is a marketing insight platform that will make use of Watson's real-time brand perception reports.

"The creativity and passion of Indian businesses to introduce cognitive-infused apps to the market is overwhelming, and the region is poised for incredible growth," said Stephen Gold, vice president for IBM Watson. "As the first Indian partners to join the Watson Ecosystem, InspireOne Technologies and TEXTIENT are excellent examples of how cognitive technology will help transform the region and the world."

IBM's Watson is no stranger to the Indian market. The company announced in late 2015 that it has partnered with 16 Indian health facilities and affiliated academic centers to help diagnose and treat cancer care. In fact, IBM is working with dozens of startups and businesses across India to integrate Watson's technology.

Shares of IBM were trading lower by more than 1.6 percent shortly after Tuesday's opening bell.

Posted-In: IBM Watson InspireOne Technologies TEXTIENT Watson Watson IndiaNews Global Tech


Related Articles (IBM)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Merck, Sanofi Exploring Potential End To Joint Venture In Europe

Investors Unimpressed With FireEye's Acquisition Announcement